Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979644 | 0.83 | ALDH1A1 (0.32) | ALDH1A1TDP1P2RX7 | |
| SCHEMBL11151827 | 0.70 | — | — | |
| SCHEMBL8039777 | 0.70 | — | — | |
| SCHEMBL7676109 | 0.69 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL8037563 | 0.68 | ALOX5 (0.33) | ALOX5 | |
| Bromide SCHEMBL8035475 | 0.68 | ALOX5 (0.33) | ALOX5 | |
| SCHEMBL8039775 | 0.68 | — | — | |
| SCHEMBL15674825 | 0.67 | ALDH1A1 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL765343 | 0.67 | ALDH1A1 (0.34) | ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL8037553 | 0.67 | ALOX5 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| WO-2009151383-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES FOR THE TREATMENT OF OBESITY AND OTHER DISEASES ASSOCIATED WITH MELANOCORTIN RECEPTOR FUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-11 | — | — | US | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
| US-20040152134-A1 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-05 | — | — | US | disclosed |
| US-20030119428-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-4148923-A | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity | SYNTHELABO (FR) | 1979-04-10 | — | — | US | disclosed |
| US-4129598-A | ANOREXIGENIC AGENTS | SYNTHELABO (FR) | 1978-12-12 | — | — | US | disclosed |
| US-3965190-A | ANOREXIGENIC | SYNTHELABO (FR) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | MC1R, MC3R, MC2R | PDE2A 2670/4885ALOX5 3431/4885ALDH1A1 2331/4885 |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | PDE2A 992/4885ALOX5 3652/4885ALDH1A1 3376/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | PDE2A 1327/4885ALOX5 3825/4885ALDH1A1 3618/4885 |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | MC1R, MC5R, MC3R | PDE2A 1307/4885ALOX5 2724/4885ALDH1A1 3502/4885 |
| US-20040152134-A1 | Bicyclic melanocortin-specific compounds | MC3R, MC5R, MC2R | PDE2A 1768/4885ALOX5 2862/4885ALDH1A1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.